Biogen Idec, Inc. (Massachusetts) (BIIB) Submits Application to FDA for Approval of PLEGRIDY (Peginterferon Beta-1a) in Multiple Sclerosis
5/21/2013 11:32:42 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WESTON, Mass.--(BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of PLEGRIDY™ (peginterferon beta-1a), the company’s pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis (RMS).
Help employers find you! Check out all the jobs and post your resume.
comments powered by